Friday, 21 Sep 2018

You are here

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp).  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (https://buff.ly/2iAFZQf)

George and colleagues analyzed the timing of inflixiamb discontinuation before elective arthroplasty and found that infliximab given within 4 weeks of elective knee or hip arthroplasty was not associated with a higher risk of short  or long-term serious infection. 

Infection risk was primarily associated with glucocorticoid use, especially >10 mg/day. The 30-day infection risk was double for short term infection (OR 2.11; 95% CI 1.30–3.40) and long term prosthetic infections (HR 2.70; 95% CI 1.30–5.60). Other risk factors for infection included elderly age, comorbidities, revision surgery, and previous hospitalized infection.

They examined infliximab patients hospitalized for infection (within 30 days) and found an event rate of 6.3% (270 out of 4,288 surgeries) They then compared infliximab use - those stopping infliximab <4 weeks of surgery and compared this cohort to those stopping infliximab versus longer 8–12 weeks.  The overall infection rate did not differ between groups and the long term prosthetic infection rates were also similar between group (2.9 per 100 person-years).

 

 

Add new comment

More Like This

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).

Biomarker Combo Predicts TNF Inhibitor Responses

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.

TNF Inhibitors Don't Increase Cancer Risk in Children

While the risk of neoplasia with tumour necrosis factor inhibitor (TNFi) use has been largely nullified in most inflammatory disorders, this risk in children is less certain. However a recent study shows no risk of increased cancer in children treated with TNFi for juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO).

Risk of Psoriasis Complicating TNF Inhibitor Therapy

A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population.